O
1.63
-0.02 (-1.21%)
| 前收盘价格 | 1.65 |
| 收盘价格 | 1.62 |
| 成交量 | 583,676 |
| 平均成交量 (3个月) | 1,446,375 |
| 市值 | 116,076,136 |
| 价格/销量 (P/S) | 17.74 |
| 股市价格/股市净资产 (P/B) | 2.63 |
| 52周波幅 | |
| 利润日期 | 10 Mar 2026 |
| 营业利益率 (TTM) | -9,653.85% |
| 稀释每股收益 (EPS TTM) | -0.340 |
| 季度收入增长率 (YOY) | -12.20% |
| 总债务/股东权益 (D/E MRQ) | 24.34% |
| 流动比率 (MRQ) | 4.93 |
| 营业现金流 (OCF TTM) | -49.55 M |
| 杠杆自由现金流 (LFCF TTM) | -27.61 M |
| 资产报酬率 (ROA TTM) | -31.37% |
| 股东权益报酬率 (ROE TTM) | -36.31% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Ovid Therapeutics Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.3
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.25 |
|
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 16.31% |
| 机构持股比例 | 55.97% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ally Bridge Group (Ny) Llc | 31 Dec 2025 | 1,785,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 4.00 (LifeSci Capital, 145.40%) | 购买 |
| 中 | 3.00 (84.05%) | |
| 低 | 2.00 (HC Wainwright & Co., 22.70%) | 购买 |
| 平均值 | 3.00 (84.05%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 1.74 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Dec 2025 | 2.00 (22.70%) | 购买 | 1.79 |
| LifeSci Capital | 22 Dec 2025 | 4.00 (145.40%) | 购买 | 1.79 |
| Roth Capital | 11 Dec 2025 | 3.00 (84.05%) | 购买 | 1.65 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合